Evolus (EOLS) Stock Forecast & Price Target

Evolus is viewed positively because its core demand appears resilient despite inflationary pressures, with management raising the lower end of 2Q revenue guidance from $327M to $330M and lifting the midpoint to $333.5M, while the U.S. neurotoxin market is still growing in the low-to-mid single digits in 1Q26. The company is also building a more durable commercial engine through portfolio expansion: Evolysse has already been purchased by ~3,500 accounts, early reorder rates are rising, accounts buying both Jeuveau and Evolysse are generating 2.5x greater year-to-date volume, and 70% of growth-bundle participants have purchased Evolysse versus 25% across the broader customer base. With two consecutive quarters of positive adjusted EBITDA, confidence in scalable margins, and a pipeline that includes Sculpt on track for FDA approval in 4Q26, Evolus has a credible path to deeper account penetration, sustainable profitability, and a more compelling multi-product aesthetics platform.

Evolus is viewed negatively because, despite 2Q26 revenue of $84.1M and 21.2% YoY growth, the company still depends heavily on Jeuveau in a cash-pay market where management acknowledges newer consumers may be staying on the sidelines and the existing treatment base has already stretched treatment intervals, limiting the durability of growth. The business also faces meaningful execution and profitability pressure, as SG&A rose to $57.1M, FY26 operating expenses are guided to $212.0M-$216.0M, and the company is only targeting a low- to mid-single digit adjusted EBITDA margin in 2026 even with improved gross margin of 69.0%. In addition, the investment case is burdened by concentration and launch risk from a slower-than-expected ramp of Evolysse, alongside exposure to competition, pricing pressure, regulatory delays, tariffs, supply chain issues, and a cash balance of $45.2M that is expected to fund operations for at least the next 12 months but leaves limited cushion if execution weakens.